Summit Therapeutics is an antibiotic developer. The company scored $50 million in funding from biotech billionaire Robert Duggan, who is described as the former chief of Pharmacyclics. The article does not disclose the funding instrument or whether additional investors participated. No details about Summit's specific antibiotic programs, clinical stage, revenue, or operating metrics were provided. The piece also omits founding year, location, and future plans for the funds.

Total raised

$50M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2019